Azitra, Inc.

Azitra is a clinical-stage precision dermatology company that leverages its extensive knowledge of genetic engineering, proteomics, and the skin microbiome to create and develop novel products for the treatment of skin diseases. The company focuses on developing genetically engineered bacteria and proteins to treat adverse skin conditions and diseases, utilizing microbial and protein engineering, artificial intelligence, and a proprietary microbial library. Azitra's initial focus is on engineered strains of Staphylococcus epidermidis for dermatologic therapies, with a pipeline including candidates ATR-12, ATR-04, and ATR-01 for conditions like Netherton syndrome, EGFR inhibitor-associated rash, and ichthyosis vulgaris.